Abstract # | Authors (reference) | Study agents | Phase | NCT |
---|---|---|---|---|
27 | Wang et al. [131] | Gilteritinib | III | 02752035 |
333 | Daver et al. [136] | Gilteritinib, Venetoclax | Ib | 03625505 |
461 | Pollyea et al. [137] | Azacitidine, Venetoclax | Sub study of III and Ib | 02203773 02993523 |
636 | Stein et al. [138] | Enasidenib | Sub study of II | 03013998 |
330 | Sallman et al. [143] | Magrolimab | Ib | 03248479 |
331 | Aldoss et al. [144] | Flotetuzumab | I | 02152956 |
460 | Ravandi et al. [145] | Vibecotamab | I | 02730312 |
165 | Abedin et al. [146] | Lintuzumab Ac225 | I | 03441048 |